GB1593568A

GB1593568A - 5-acetyl-4-hydroxy-3-(1-phenylaminoethylidene)-2h-pyran-2,6(3h)-diones

Info

Publication number: GB1593568A
Application number: GB17031/78A
Authority: GB
Original assignee: SmithKline Corp
Current assignee: GlaxoSmithKline LLC
Priority date: 1977-04-29
Filing date: 1978-04-28
Publication date: 1981-07-22
Also published as: DE2818984A1; JPS6244550B2; FR2388808A1; FR2388808B1; JPS53135982A

Description

(54) 5-ACETYL-4-HYDROXY-3- ( 1-PHENYLAMINOETHYLIDENE)-2H-PYRAN- 2,6(3H)-DIONES.

(71) We, SMITHKLINE CORPORATION, of 1500 Spring Garden Street, City of Philadelphia, Commonwealth of Pennsylvania 19101, United States of America, a corporation organized under the laws of the Commonwealth of Pennsylvania, one of the United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement: This invention relates to substituted 2H-pyran-2,6(3H)-dione derivatives which are useful for inhibiting the symptoms of an allergic response resulting from an antigen-antibody reaction. More specifically, the compounds of this invention are believed to be effective by inhibiting the release and/or formation and release of pharmacologically active mediators such as histamine, serotonin and slow-reacting substance of anaphylaxis (SRS-A) from effector cells which are produced and/or released as a result of an interaction of antigen and specific antibody fixed to the cell surface (allergic reaction). These properties enable the subject compounds to be useful in various allergic diseases such as asthma, rhinitis and urticaria.

The compounds of this invention are represented by the following general structural formula:

FORMULA I wherein: R1 represents lower alkvl succinamoyl (-NHCOCH,-CH,COOR?) ketomalonamoyl (-NHCOCOCOOH) or glyceramoyl

R2 represents hydrogen or, when R, is glyceramoyl, also represents amino or glyceramoyl; and R3 represents lower alkyl having one or two carbon atoms.

Particular compounds of this invention represented by formula I above are 3methylsuccinamoyl, 3-ketomalonamoyl, 3-glyceramoyl, 3,5-bis-glyceramoyl and 3glyceramoyl-5-amino derivatives.

The compounds of formula I wherein R2 is hydrogen or glyceramoyl are conveniently prepared as shown in the following scheme:

in which R1 is as defined above. Thus, 3,5-diacetyl-4,6-dihydroxy-2H-pyran-2-one and the appropriately substituted aniline are heated at reflux in an inert organic solvent such as benzene, toluene, ethanol or methanol for from one to three hours to give the products.

Compounds of formula I wherein R1 is glyceramoyl and R2 is amino are conveniently prepared by reacting 3 ,5-diacetyl-4 ,6-dihydroxy-2H-pyran-2-one with the appropriately substituted nitroaniline followed by catalytic hydrogenation for example with palladium-oncarbon catalyst.

Mono-and di-alkali metal salts of the compounds of formula I, such as the mono-and di-sodium or potassium salts are readily obtainable by treatment with the appropriate alkali metal alkoxide, for example methoxide, in an alkanol solvent such as methanol.

The pyran-2-one starting material indicated above is obtained by reaction of acetonedicarboxylic acid with acetic anhydride in sulfuric acid at elevated temperature. The reaction product actually has the tautomeric structure as shown below:

however for convenience it is designated herein as 3,5-diacetyl-4,6-dihydroxy -2H-pyrdn-2- one. Accordingly, the reactionof this product with an aniline as shown above gives a product having the tautomeric structures as shown below:

in which R1 and R2 are as defined above for formula I. For convenience we have chosen to dse one' tautomeric'form, namely the intermediate enamine pyran-2,6-dione 'structure, to represent all of the compounds formed by reaction of (E) with the aniline, as indicated by formula I above. It will be apparent however to one skilled in the art that the more complete representation of the compounds of formula I is shown by the tautomerization i).

The substituted aniline starting materials used herein are conveniently prepared by well-known preparative methods.

Wiley, R.H. et al. A Org. Chem. 21:686-688 (1956) has reported the reaction of amines with reaction product of acetonedicarboxylic acid and acetic' anhydride, the latter designated 5-carboxydehydroacetic acid. Similarly, Kiang, A.K. et al. J. Chem. Soc. (c) pp.

2721-6 (1971) has disclosed such reaction products with amines. However there is no disclosure of products represented by formula I.

The inhibitory activity of the compounds of this invention on mediator release in sensitized tissues, thereby inhibiting the effects of the allergic reaction, is measured by the ability of the test compound to inhibit the passive cutaneous anaphylaxis (PCA) reaction in rats. In this test system, titered and appropriately diluted serum (from rats previously immunized by the intraperitoneal injection of ovalbuminaluminum hydroxide or ovalbumin-i.m.-Bordatella pertussis U.S.P. i.p.-and N-Brasiliensis i.p.) containing reaginic antibodies directed against ovalbumin is injected intradermally at four sites on the shaved backs of normal adult male rats. Forty-eight hours later the animals are injected intravenously.with 0.5 ml. of isotonic saline solution containing 5 mg. of the ovalbumin antigen and 5 mg. of Evans blue dye. Chemical mediators such as histamine and serotonin which are released at the sensitized sites as a result of a local cellular anaphylaxis, cause an increase in capillary permeability with resultant leakage of plasma and formation of a wheal. The wheal is visualized by the plasma protein-bound Evans blue dye. Under conditions of the test, the average control wheal is approximately 12 x 12 mm. Thirty minutes following antigen challenge, the animals are killed, the dorsal skin is reflected and the diameter of the wheals recorded. A test compound is administered intravenously, initially at 0.5 minutes prior to antigen challenge, (longer pretreatment times and other routes of drug administration, i.e. oral or intraperitoneal, may be employed).. Percent inhibition is calculated from the difference in mean average wheal diameter between a treated group and saline or appropriate diluent controls.

The interruption by a test compound of the sequence of events triggered by reaginic antibody-antigen interaction on the surface of sensitized cells is indicative of utility in inhibiting the symptoms which result from an immediate-type allergic response.

The compounds of formula I administered intravenously to rats at doses of from 0.001 to 10 mg/kg produce marked inhibition of the PCA reaction. For example, 5-acetyl-3-[1-(3 methylsuccinamoylphenylamino)ethylidene]-4-hydroxy-2H-pyran-2 ,6, (3H)-dione pro duced 58% inhibition of the rat PCA wheal at 0.25 mg/kg, i.v. Another compound, 5-acetyl-3- [- (3-ketomalonamoylphenylamino)ethylidenej-4-hydroxy-2H-pyran-2 ,6(3H)- dione, produced 55% inhibition of the rat PCA wheal at 0.0312 mg/kg, i.v. and 5-acetyl-3-[ 1-(3-glyceramoylphenylamino)ethylidene]-4-hydroxy-2H-pyran-2 ,6(3H)-dione produced 63% inhibition of the rat PCA wheal at 0.0312 mg/kg, i.v. Also, 5-acetyl-3-[1 (3,5-bis-glyceramoylphenylamino) ethylidene]-4-hydroxy-2H-pyran-2,6(3H)-dione pro duced 53% inhibition of the rat PCA wheal at 0.001 mg/kg, i.v. and 5-acetyl-3-[1-(3 glyceramoyl-5-aminophenylamino)ethylidene]-4-hydroxy-2H-pyran-2,6(3H)-dione pro duced 77% inhibition of the rat PCA wheal at 0.062 mg/kg, i.v.

In testing for mechanism of action the compounds of formula I, following i.v.

administration at the same dose and pretreatment time which exhibited significant inhibition of the rat 48-hour PCA reaction, do not provide comparable inhibition of wheals of equal severity produced in rats by the intracutaneous administration of histamine and serotonin.

Upon oral administration, 5-acetyl-3-[1-(3-glyceramoylphenylamino)ethylidene]-4 hydroxy-2H-pyran-2,6(3H)-dione produced 55% inhibition in the rat 48-hour PCA system at 25 mg/kg and a pretreatment time of 15 minutes. Similarly, 5-acetyl-3-[1-(3,5-bis glyceramoylphenylamino)ethylidene]-4-hydroxy-2H-pyran-2,6(3H)-dione produced 83% inhibition after oral administration of 3.12 mg/kg and 5-acetyl-3-[1-(3-glyceramoyl-5 aminophenylamino)ethylidene]-4-hydroxy-2H-pyran-2,6(3H)-dione produced 61% inhibi tion after oral administration of 25 mg/kg(both pretreatment times of 15 minutes).

The compounds of this invention may be administered in conventional pharmaceutical compositions comprising an appropriate amount of a compound of formula I in association with a pharmaceutical carrier of diluent. The nature of the composition and the pharmaceutical carrier or diluent will of course depend upon the intended route of administration, i.e. orally, parenterally or by inhalation. Usually a compound is administered to an animal in a composition comprising an amount sufficient to produce an inhibition of the symptoms of an allergic response. When employed in this manner, the dosage of the composition is such that from 0.5 mg. to 500 mg. of active ingredient are administered at each administration. For convenience equal doses will be administered 1 to 4 times daily with the daily dosage regimen being 0.5 mg. to 2000 mg.

In general, particularly for the prophylactic treatment of asthma, the compositions will be in a form suitable for administration by inhalation. Thus the compositions will comprise a suspension or solution of the active ingredient in sterile water for administration by means of a conventional nebulizer. Alternatively the compositions will be in the form of an aerosol formulation and will comprise a suspension or solution of the active ingredient in a conventional liquified propellant such as dichlorodifluoromethane or chlorotrifluoroethane to be administered from a pressurized container. The compositions may also comprise the solid active ingredient diluted with a solid diluent, e.g. lactose, for administration from a powder inhalation device. In the above compositions, the amount of carrier or diluent will vary but preferably will be the major proportion of a suspension or solution of the active ingredient. When the diluent is a solid it may be present in less, equal or greater amounts than the solid active ingredient.

A wide variety of other pharmaceutical forms can be employed. Thus, if a solid carrier is used the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form, or in the form of a troche or lozenge for oral administration. The amount of solid carrier will vary widely but preferably will be 25 mg. to 1 g. If a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an impule, or an aqueous or nonaqueous liquid suspension.

Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Exemplary of liquid carriers are syrup, peanut oil, olive oil and water. Similarly the carrier or diluent can include any time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.

The pharmaceutical preparations thus described are made following the conventional techniques of the pharmaceutical chemist involving mixing, granulating and compressing when necessary, or variously mixing and dissolving the ingredients as appropriate to the desired end product.

The compounds of this invention are useful for inhibiting the symptoms of an allergic response resulting from an antigen-antibody reaction by administering a therapeutically effective amount for producing said inhibition of a compound of formula I, preferably in the form of a pharmaceutical composition. The administration may be carried out in dosage units at suitable intervals or in single doses as needed. Usually the compounds of this invention will be administered when relief of allergic symptoms is specifically required, however, the compounds can also be given as continuous or prophylactic treatment. A particular application to administer the compounds to relieve or prevent allergic airway obstruction by administering a therapeutically effective amount at suitable intervals. It is within the skill of the art to determine by routine experimentation the effective dosage to be administered from the dose range set forth above, taking into consideration such factors as the degree of severity of the allergic condition being treated, and so forth.

The following Examples illustrate the invention.

EXAMPLE 1 To a solution of 6.31 g (0.045 mol) of m-nitroaniline in 10 ml. of,anhydrous pyridine at 5"C. was added 6.8 g. (0.045 mol) of methylsuccinoyl chloride, dropwise with stirring. The mixture was allowed to warm to 25"C. for 30 minutes and then poured into a mixture of 100 ml. of 3N hydrochloric acid and 100 g. of ice. The precipitate was filtered to give 3-nitro-N-methylsuccinoylaniline, m.p. 120-126"C.

A solution of 1.0 g (0.0028 mol of 3-nitro-N-methyl-succinoylaniline in 50 ml. of methanol was hydrogenated over 100 mg. of 10% palladium-on-carbon at 50 psi. Reduction was complete in 45 minutes, the catalyst was filtered and to the filtrate containing the 3-methylsuccinamoylaniline was added 0.6 g (0.003 mol) of 3,5-diacetyl-4,6-dihydroxy-2Hpyran-2-one. The mixture was heated under reflux for one hour, cooled and the product filtered to yield 5acetyl-4-hydroxy-3-[1-(3-methylsucdnamoylphenylamino)ethylidene]- 2H)-pyran-2,6(3H)-dione, m.p. 208-210"C.

Anal. Calc'd: C 57.69 H 4.84 N 6.73 Found: 57.39 4.92 6.86 Similarly, employing ethylsuccinoyl chloride and further reacting the substituted aniline as outlined above furnishes the corresponding product 5-acetyl-4-hydroxy-3-[1-(3- ethylsuccinamoylphenylamino)ethylidene]-2H-pyran-2,6-(3H)-dione.

EXAMPLE 2 To a solution of 13.8 g (0.10 mol) of m-nitroaniline in 100 ml. of diethyl ether and 30 ml.

of ethyl acetate was added 9.0 g (0.10 mol) of acryloyl chloride and a solution of 4.0 g. (0.10 mol) of sodium hydroxide in 20 ml. of water. The mixture was stirred overnight (18 hours) at ambient temperature and the precipitate filtered to give N-propenoyl-3-nitroaniline.

Water (400 ml.) and 250 g. of ice were added to a solution of 10.0 g. (0.055 mol) of N-propenoyl-3-nitroaniline in 500 ml. of tert.-butyl alcohol. The mixture was stirred vigorously and maintained at 5"C. while a solution of 12 g. (0.075 mol) potassium permanganate and 5.0 g. (0.125 mol) of sodium hydroxide in 400 ml. of water was added.

After stirring for 5 minutes the reaction was stopped by bubbling sulfur dioxide gas through the mixture until the color became a pale yellow. The mixture was chilled and crude N-(2-carboxy-2-oxoacetyl)-3-nitroaniline precipitated. This was filtered and the filtrate containing N-(2 ,3-dihydroxypropionyl)-3-nitroaniline was set aside.

Crude N-(2-carboxy-2-oxoacetyl)-3-nitroaniline was purified by dissolving in diethyl ether saturated with hydrogen chloride, filtration and evaporation of the filtrate. The residue was slurried in 10 volumes of isopropyl alcohol, filtered and washed with dilute (3N) hydrochloric acid to give pure N-(2-carboxy-2-oxoacetyl)-3-nitroaniline, m.p. 110 C.

A solution of 1.2 g. (0.005 mol) of N-(2-carboxy-2-oxoacetyl)-3-nitroaniline in 60 ml. of methanol was hydrogenated over 200 mg. of 10% palladium-on-carbon at 50 psi. When the theoretical amount of hydrogen had been absorbed the reduction was stopped, 40 ml. of 5% aqueous sodium bicarbonate solution was added and the catalyst filtered. The filtrate was evaporated to approximately 50 ml., acidified with 3N hydrochloric acid to pH 2 and the resulting precipitate filtered, washed with water and dried to give N-(2-carboxy-2oxoacetyl)-1,3-phenylene diamine, m.p. 246"C.

A mixture of 0.65 g (0.003 mol) of 3,5-diacetyl-4,6-dihydroxy-2H-pyran-2-one, 0.6 g.

(0.003 mol) of the above prepared phenylenediamine and 30 ml. of methanol was heated under reflux for 1.5 hours. The reaction mixture was cooled, filtered and the residue washed with methanol to yield 5-acetyl-4-hydroxy-3-[1-(3 ketomalonamoylphenylamino)ethylidenej-2H-pyran-2,6(3H)-dione, m.p. 218"C.

Anal. Calc'd: C 53.74 H 3.51 N 6.96 Found: 53.76 3.85 7.21 EXAMPLE 3 The aqueous filtrate from Example 2 containing N-(2,3-dihydroxypropionyl)-3nitroaniline was extracted three times with 250 ml. of ethyl acetate. The combined organic layers were dried over magnesium sulfate and evaporated. The residue was stirred with 75 ml. of isopropyl alcohol and filtered to give pure N-(2,3-dihydroxypropionyl)-3nitroaniline, m.p. 143-144"C.

A solution of 1.13 g. (0.005 mol) of the above 3-nitroaniline in 60 ml. of methanol was hydrogenated over 200 mg. of 10% palladium-on-carbon at 50 psi. Reduction was complete in 30 minutes, the catalyst filtered and the solvent evaporated to approximately one-half volume. To this solution was added 1.06 g. (0.005 mol) of 3,5-diacetyl-4,6-dihydroxy-2Hpyran-2-one and the mixture heated under reflux for 1.5 hours. The reaction mixture was cooled, the precipitate filtered, and the solid washed with methanol and then dried to yield 5-acetyl-4-hydroxy-3-[1-(3-glyceramoylphenylamino)-ethylidene]-2H-pyran-2,6(3H)- dione, m.p. 218"C.

Anal. Calc'd: C 55.39 H 4.65 N 7.18 Found: 55.04 4.79 7.08 EXAMPLE 4 Following the procedures of Examples 1-3 and employing o-nitroaniline or p-nitroaniline as the starting reagent there is obtained the corresponding isomeric products upon reaction with 3 ,5-diacetyl-4,6-dihydroxy-2H-pyran-2-one.

As a specific embodiment of a composition of this invention, an active ingredient such as 5-acetyl-4-hydroxy-3-[1-(3-methylSuccinamoylphenylamino)ethylidene]-2H-pyran-2,6(3H)- dione is dissolved in sterile water at a concentration of 0.5% and aerosolized from a nebulizer operating at an air flow adjusted to deliver the desired aerosolized weight of drug.

For oral administration, a composition such as the following can be prepared.

Ingredients Mg.lTablet 5-Acetyl-4-hydroxy-3-[1- 10 (3-glyceramoylphenyl- amino)ethylidene] -2H pyran-2,6(3H)-dione Calcium sulfate, dihydrate 150 Sucrose 25 Starch 15 Talc 5 Stearic acid 3 The sucrose, calcium sulfate and active ingredient are thoroughly mixed and granulated with hot 10% gelatin solution. The wetted mass is passed through a #6 mesh screen directly onto drying trays. The granules are dried at 1200F. and passed through a #20 mesh screen, mixed with the starch, talc and stearic acid and compressed into tablets.

EXAMPLE 5 To a solution of 0.5 g (2.9 mmole) of 2,2-dimethyl-1,3-dioxolane-4-carboxylic acid in 2 ml of methylene chloride, at OOC, was added a solution of 0.216 g of 3,5-diaminonitrobenzene (1.3 mmole) in 2 ml of methylene chloride and 1 ml of pyridine, followed by 0.61 g (3.0 mmole) of dicyclohexylcarbodiimide. The mixture was stirred 72 hours, diluted with ethyl acetate, filtered and the filtrate evaporated to dryness in high vacuum. The residue was chromatographed over silica gel; elution with 9:1 chloroform-ethyl acetate gave two fractions. The first fraction, 170 mg was the bis-acylated material. The second fraction was evaporated to dryness to give 250 mg of N-(3-amino-5-nitrophenyl)-2,2-dimethyl-1,3 dioxolane-4-carboxamide.

A mixture of 0.915 g (3.3 mmole) of N-(3-amino-5-nitrophenyl)-2,2-dimethyl-1,3dioxolane-4-carboxamide in 20 ml of 50% acetic acid was heated on a steam bath for 1 hour then stored over a weekend. The solvents were removed in high vacuum to afford the product, N-(2,3-dihydroxypropionyl)-3-amino-5-nitroaniline, as an oil which was used without further purification.

A mixture of 785 mg (3.3 mmole) of N-(2,3-dihydroxypropionyl)-3-amino-5-nitroaniline and 690 mg (3.3 mmole) of 3,5-diacetyl-4,6-dihydroxy-2H-pyran-2-one in 30 ml of methanol was heated under reflux for 30 minutes. After cooling, the crystalline product was filtered and dried in vacuum to give 616 mg of 5-acetyl-4-hydroxy-3-1-(3-glyceramoyl-5- nitrophenyl-amino)ethylidene -2H-pyran-2,6(3H)- -2H-p ran-2,6(3H)-dione.

A solution of 580 mg (1.3 mmole) of the above nitro substituted product in 150 ml of acetic acid was hydrogenated over 100 mg of 10% palladium-on-carbon at 40 psi of hydrogen for 15 minutes. The catalyst was removed and the filtrate evaporated to dryness.

The residue was titurated with cold acetone-methanol, then crystallized from methanolether to give 148 mug crystalline material, 5-acetyl-3-[1-(5-amino-3-glyceramoylphenylamino)ethylidene4-hydroxy-2H-pyran-2,6(3H)-dione m.p. 163"C. (dec.).

EXAMPLE 6 A solution of 1.0 g (2.4 mmole) of N,N'-(5-nitro-1,3-phenylene)bis-2,2-dimethyl-1,3- dioxolane-4-carboxamide (the bis-acylated material from Example 5) in 20 ml of 50% acetic acid was heated on a steam bath for 30 minutes and then stirred at room temperature for 72 hours. The mixture was evaporated to dryness and the residue triturated with acetonitrile to give 700 mg of crystalline material, 3,5-bis(2,3-dihydroxypropionylamino)nitrobenzene, m.p. 224-230 C.

A solution of 3.5 g (10.6 mmole) of the above prepared nitrobenzene in 200 ml of methanol containing 5 ml of water was hydrogenated over 470 mg of 10% palladium-oncarbon at 50 psi of hydrogen for 1-1/2 hours. The catalyst was removed by filtration and the residue evaporated to dryness to give 3.95 g of 3,5-bis(2,3dihydroxypropionylamino)aniline which was used directly in the next step.

A mixture of 3,5-diacetyl-4,6-dihydroxy-2H-pyran-2-one (0.578 g., 2.73 mmole) and 0.816 g. (2.73 mmole) of the above prepared aniline in 20 ml of methanol was refluxed for one hour under argon. lhe reaction mixture was cooled, the precipitate filtered, and the solid washed with methanol and then dried to yield 5-acetyl-4-hydroxy-3-[1-(3,5-bisglyceramoyl-phenylamino)ethylidene]-2H-pyran-2,6(3H)-dione, m.p. 231"C.

WHAT WE CLAIM IS: 1. -A compound represented by the formula:

wherein: R1 represents lower alkyl succinamoyl, ketomalonamoyl or glyceramoyl: R2 represents hydrogen or, when Rt is glyceramoyl, also represents amino or glyceramoyl; and the lower alkyl moiety has one or two carbon atoms, or a mono-or di-alkali metal salt of said compound.

2. A compound according to claim 1 in which R1 is in the 3-position.

3. A compound according to claim 1 or claim 2 in which R2 is hydrogen.

4. A compound according to claim 3 in which R1 is methylsuccinamoyl.

5. A compound according to claim 3 in which R1 is ketomalonamoyl.

6. A compound according to claim 3 in which R1 is glyceramoyl.

A compound according to claim 2 in which Rl is glyceramoyl and R2 is amino.

7. A compound according to claim 3 in which R1 is glyceramoyl and R2 is amino.

8. A compound according to claim 2 in which R1 and R2 are glyceramoyl.

9. A pharmaceutical composition for inhibiting the symptoms of an immediate-type allergic response comprising a nontoxic pharmaceutical carrier or diluent and an amount sufficient to produce said inhibition of a compound according to claim 1.

10. A pharmaceutical composition according to claim 9 in a form suitable for administration by inhalation.

11. A pharmaceutical composition according to claim 9 comprising a solution or suspension of the active ingredient in sterile water.

12. A pharmaceutical composition according to claim 9 in the form of an aerosol formulation.

13. A pharmaceutical composition according to claim 9 in which the pharmaceutical carrier or diluent is a solid.

14. A pharmaceutical composition according to claim 9 in which Rl is 3 methylsuccinamoyl.

15. A pharmaceutical composition according to claim 9 in which R1 is 3ketomalonamoyl.

16. A pharmaceutical composition according to claim 9 in which R1 is 3-glyceramoyl and R2 is hydrogen.

17. A pharmaceutical composition according to claim 9 in which R1 is 3-glyceramoyl and R2 is amino.

18. A pharmaceutical composition according to claim 9 in which Rl is 3-glyceramoyl and R2 is glyceramoyl.

19. A pharmaceutical composition according to claim 9 in dosage unit form and in which the active ingredient is in an amount of from 0.5 mg. to 500 mg. per dosage unit.

20. A process for the preparation of compounds of the formula:

wherein Rl represents lower alkyl succinamoyl, ketomalonamoyl or glyceramoyl and R2 is hydrogen or is glyceramoyl when R1 is glyceramoyl and the lower alkyl moiety has one or two carbon atoms, which comprises reacting 3,5-diacetyl-4,6-dihydroxy-2H-pyran-2-one with an aniline of the formula:

**WARNING** end of DESC field may overlap start of CLMS **.

Claims

**WARNING** start of CLMS field may overlap end of DESC **. one hour under argon. lhe reaction mixture was cooled, the precipitate filtered, and the solid washed with methanol and then dried to yield 5-acetyl-4-hydroxy-3-[1-(3,5-bisglyceramoyl-phenylamino)ethylidene]-2H-pyran-2,6(3H)-dione, m.p. 231"C. WHAT WE CLAIM IS:

1. -A compound represented by the formula:

2. A compound according to claim 1 in which R1 is in the 3-position.

3. A compound according to claim 1 or claim 2 in which R2 is hydrogen.

4. A compound according to claim 3 in which R1 is methylsuccinamoyl.

5. A compound according to claim 3 in which R1 is ketomalonamoyl.

6. A compound according to claim 3 in which R1 is glyceramoyl.

A compound according to claim 2 in which Rl is glyceramoyl and R2 is amino.

7. A compound according to claim 3 in which R1 is glyceramoyl and R2 is amino.

8. A compound according to claim 2 in which R1 and R2 are glyceramoyl.

20. A process for the preparation of compounds of the formula:

in which R1 and R2 are as defined above.

21. The process according to claim 20 in which the reactants are heated at reflux in an inert organic solvent for from one to three hours.

22. A process for the preparation of compounds of the formula:

wherein R1 is glyceramoyl and R2 is amino, which comprises reacting 3,5-diacetyl-4,6dihydroxy-2H-pyran-2-one with an aniline of the formula:

in which R1 is glyceramoyl, followed by catalytic hydrogenation of the nitro substituted derivative.

23. The process according to claim 22 in which the initial reactants are heated at reflux in an inert organic solvent for from 30 minutes to three hours.

24. The process according to claim 22 or 23 in which the hydrogenation is carried out with palladium-on-carbon catalyst.

25. A process for preparing a compound according to claim 3 substantially as hereinbefore described in any one of Examples 1 to 3.

26. A process for preparing a compound according to claim 1 substantially as hereinbefore described in Example 5 or Example 6.

27. A compound according to claim 1 whenever prepared by a process according to any one of claims 20 to 26.